David J. Mcconkey, Phd, On Treating Bladder Cancer With Checkpoint Inhibitors

David J. McConkey, PhD, on treating bladder cancer with checkpoint inhibitors

David J. McConkey, PhD, on which drugs have the highest potential to impact bladder cancer treatment

David J. McConkey, PhD, on non-invasive imaging and monitoring metastatic bladder cancer

David J. McConkey, PhD, on the responses to immunotherapy for varied bladder cancer subtypes

David J. McConkey, PhD, discusses how genomics helps us understand heterogeneity in bladder cancer

David J. McConkey, PhD, on the influence of genomics for the treatment of bladder cancer subtypes

Use of Immune Checkpoint Inhibitors for Bladder Cancer

Dr. Plimack on Choosing a Checkpoint Inhibitor in Bladder Cancer

How can we continue the success of checkpoint inhibitors for bladder cancer treatment?

How can we improve responses to immunotherapy in patients with bladder cancer?

Treatment of Bladder Cancer-Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors for Advanced Bladder Cancer

The difficulties in treating bladder cancer with immunotherapy

Dr. Siefker-Radtke on PD-L1 as a Biomarker in Bladder Cancer

Dr. Apolo on Toxicity Challenges With Checkpoint Inhibitors in Bladder Cancer

Dr. Siefker-Radtke on FDA Approval of Durvalumab in Bladder Cancer

‘It’s all about checkpoint inhibitors’ – Rob Jones on bladder cancer during ASCO 2017

Practical Considerations With Checkpoint Inhibitors in Bladder Cancer

Navigating Clinical Trials in Bladder Cancer

Johns Hopkins Medicine

Bladder Cancer: Immunotherapy in the Perioperative Setting